Overview

Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy

Status:
RECRUITING

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, prospective, non-randomized, open-label, phase 2 clinical study to evaluate the efficacy and safety of tislelizumab in patients with de novo Hodgkin Lymphoma deemed ineligible to frontline chemotherapy.

Phase:

PHASE2

Details

Lead Sponsor:

Fondazione Italiana Linfomi - ETS

Treatments:

tislelizumab